United States Interventional Cardiology Market Outlook to 2025
Orbisresearch.com published “Interventional Cardiology Market” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
(EMAILWIRE.COM, April 24, 2018 ) GlobalData’s new report, United States Interventional Cardiology Market Outlook to 2025, provides key market data on the United States Interventional Cardiology market. The report provides value, in millions of US dollars, volume (in units) and average prices (USD) within market segments -Arteriotomy Closure Devices, Cardiac Catheters, Coronary Guidewires, Coronary Stents, Intravascular Ultrasound Systems (IVUS), PTCA Balloons Catheters and PTCA Drug Eluting Balloon (DEB) Catheters.
The report also provides company shares and distribution shares data for each of these market segments, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.
Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.
Request a Sample PDF of this Report@ http://orbisresearch.com/contacts/request-sample/2121795
Scope:
- Market size and company share data for Interventional Cardiology market segments - Arteriotomy Closure Devices, Cardiac Catheters, Coronary Guidewires, Coronary Stents, Intravascular Ultrasound Systems (IVUS), PTCA Balloons Catheters and PTCA Drug Eluting Balloon (DEB) Catheters.
- Annualized market revenues (USD million) and volume (units) data for each of the market segments. Data is provided from 2015 to 2025.
- 2017 company share and distribution share data for Interventional Cardiology market.
- Global corporate-level profiles of key companies operating within the United States Interventional Cardiology market.
- Key players covered include Abbott Laboratories, Boston Scientific Corp, Medtronic plc, and Others.
Reasons to buy:
- Develop business strategies by identifying the key market segments poised for strong growth in the future.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the market.
- Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.
Have any query? Feel free to ask us@ http://orbisresearch.com/contacts/enquiry-before-buying/2121795
Companies Mentioned:
Abbott Laboratories
Terumo Corp
Boston Scientific Corp
Medtronic Plc
Cook Medical Inc
Asahi Kasei Corp
Philips Healthcare
Cardinal Health Inc
Some Points from TOC:
1 Table of Contents 2
2 Introduction 8
3 Interventional Cardiology Market, United States 13
4 Overview of Key Companies in United States, Interventional Cardiology Market 48
5 Interventional Cardiology Market Pipeline Products 50
6 Financial Deals Landscape 51
7 Recent Developments 70
7.1 Corporate Communications 70
7.1.1 Mar 30, 2018: Abiomed to Appoint New Chief Financial Officer Todd A. Trapp 70
7.1.2 Feb 27, 2018: Z-Medica Announces Appointment Of Eric Compton As CEO 70
7.1.3 Feb 21, 2018: Endologix Announces Resignation Of John McDermott As Chief Executive Officer 70
7.1.4 Feb 20, 2018: AtriCure Names Scott Drake Board Chairman 71
7.1.5 Feb 12, 2018: Integer Elects James Hinrichs to its Board of Directors 71
7.1.6 Feb 02, 2018: Cardiovascular Systems Appoints Jeff Points as Chief Financial Officer 72
7.1.7 Jan 29, 2018: Endologix Names Greg Morrow As Chief Marketing Officer 72
7.1.8 Jan 29, 2018: Endologix Appoints Greg Morrow as Chief Marketing Officer 73
7.1.9 Jan 24, 2018: Cardiovascular Systems Appoints Rhonda Robb as New Chief Operating Officer 73
7.1.10 Jan 03, 2018: Tryton Medical Announces New CEO and President 74
7.1.11 Jan 02, 2018: Integer Names Kirk Thor Chief Human Resources Officer 74
7.1.12 Nov 22, 2017: IMRIS Appoints Mark Strong as Senior Vice President - Research & Development 74
7.1.13 Nov 20, 2017: Follicum applies for the start of a Phase II study at the German Medicines Agency 75
7.1.14 Oct 31, 2017: Luminex Corporation Receives FDA Clearance for ARIES Group A Strep Assay 75
7.1.15 Oct 19, 2017: Endologix Appoints John Onopchenko as Chief Operating Officer 77
7.1.16 Oct 04, 2017: Boston Scientific Appoints Desiree Ralls-Morrison General Counsel and Corporate Secretary 77
7.1.17 Oct 02, 2017: Jeffrey H. Burbank Joins CryoLife Board of Directors 78
7.1.18 Sep 26, 2017: Edward Parent Appointed Director of Quality Assurance at TissueGen 78
7.1.19 Aug 28, 2017: Abiomed Announces Resignation of Chief Financial Officer and Welcomes Back Former Chief Financial Officer as Consultant 79
7.1.20 Aug 08, 2017: John K. Bakewell Joins Corindus Vascular Robotics Board of Directors 79
7.1.21 Jul 31, 2017: Atara Biotherapeutics Announces Two Presentations at MSParis2017, Including Updated, Interim Results from a Phase 1 Study of Autologous ATA188 in Patients with Progressive Multiple Sclerosis 80
7.1.22 Jul 18, 2017: AtriCure Announces Hiring of Chief Technology Officer 81
7.1.23 Jul 17, 2017: Integer Announces Appointment of Joseph W. Dziedzic as President and Chief Executive Officer 81
7.1.24 Jun 20, 2017: Medtronic VP and GM Sandra Lesenfants Joins Osprey Board 82
7.1.25 Jun 20, 2017: Medtronic VP and GM Sandra Lesenfants J oins Osprey Board 82
7.1.26 Jun 14, 2017: Spectranetics Announces Election of New Chairperson of the Board of Directors 83
7.1.27 May 26, 2017: Merit Medical Announces Appointment of New Director 83
7.1.28 Apr 19, 2017: TissueGen appoints New Faces for Growing Sales Team 83
7.2 Financial Announcements 84
7.2.1 Mar 14, 2018: Corindus Reports Fourth Quarter and Full Year 2017 Results 84
7.2.2 Mar 07, 2018: CryoLife Reports Fourth Quarter and Full Year 2017 Results 84
7.2.3 Feb 26, 2018: AtriCure Announces Fourth Quarter and Full Year 2017 Financial Results 85
7.2.4 Feb 22, 2018: Integer Holdings Reports Results for Fourth Quarter and Full Year 2017 86
7.2.5 Feb 21, 2018: Endologix Reports Fourth Quarter and Fiscal Year 2017 Financial Results 87
7.2.6 Feb 20, 2018: Philips increases Green Revenues to EUR 10.7 billion, 60% of total sales in 2017 88
7.2.7 Feb 08, 2018: Surmodics Reports First Quarter Fiscal 2018 Results, Updates Fiscal 2018 Guidance 89
7.2.8 Feb 07, 2018: Cardiovascular Systems Reports Fiscal 2018 Second-Quarter Financial Results 89
7.2.9 Feb 01, 2018: Boston Scientific Announces Results for Fourth Quarter and Full Year 2017 90
7.2.10 Feb 01, 2018: Abiomed Announces Q3 FY 2018 Record Revenue of $154 Million, Up 34% Over Prior Year 92
7.2.11 Jan 23, 2018: Glytec's Software Yields Superior Patient Outcomes According to Four New Studies in Journal of Diabetes Science and Technology 92
7.2.12 Jan 09, 2018: Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year Ended December 31, 2017 94
7.2.13 Jan 08, 2018: AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2017 94
7.2.14 Jan 08, 2018: Abiomed Announces Preliminary Q3 FY 2018 Revenue of $154M, Up 34% Over Prior Year 95
7.2.15 Jan 04, 2018: AngioDynamics Reports Fiscal 2018 Second Quarter Financial Results 95
Continue…
Note: If you have any special requirements, please let us know and we will offer you the report as you want.
Browse full report with TOC@ http://orbisresearch.com/reports/index/united-states-interventional-cardiology-market-outlook-to-2025
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
The report also provides company shares and distribution shares data for each of these market segments, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.
Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.
Request a Sample PDF of this Report@ http://orbisresearch.com/contacts/request-sample/2121795
Scope:
- Market size and company share data for Interventional Cardiology market segments - Arteriotomy Closure Devices, Cardiac Catheters, Coronary Guidewires, Coronary Stents, Intravascular Ultrasound Systems (IVUS), PTCA Balloons Catheters and PTCA Drug Eluting Balloon (DEB) Catheters.
- Annualized market revenues (USD million) and volume (units) data for each of the market segments. Data is provided from 2015 to 2025.
- 2017 company share and distribution share data for Interventional Cardiology market.
- Global corporate-level profiles of key companies operating within the United States Interventional Cardiology market.
- Key players covered include Abbott Laboratories, Boston Scientific Corp, Medtronic plc, and Others.
Reasons to buy:
- Develop business strategies by identifying the key market segments poised for strong growth in the future.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the market.
- Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.
Have any query? Feel free to ask us@ http://orbisresearch.com/contacts/enquiry-before-buying/2121795
Companies Mentioned:
Abbott Laboratories
Terumo Corp
Boston Scientific Corp
Medtronic Plc
Cook Medical Inc
Asahi Kasei Corp
Philips Healthcare
Cardinal Health Inc
Some Points from TOC:
1 Table of Contents 2
2 Introduction 8
3 Interventional Cardiology Market, United States 13
4 Overview of Key Companies in United States, Interventional Cardiology Market 48
5 Interventional Cardiology Market Pipeline Products 50
6 Financial Deals Landscape 51
7 Recent Developments 70
7.1 Corporate Communications 70
7.1.1 Mar 30, 2018: Abiomed to Appoint New Chief Financial Officer Todd A. Trapp 70
7.1.2 Feb 27, 2018: Z-Medica Announces Appointment Of Eric Compton As CEO 70
7.1.3 Feb 21, 2018: Endologix Announces Resignation Of John McDermott As Chief Executive Officer 70
7.1.4 Feb 20, 2018: AtriCure Names Scott Drake Board Chairman 71
7.1.5 Feb 12, 2018: Integer Elects James Hinrichs to its Board of Directors 71
7.1.6 Feb 02, 2018: Cardiovascular Systems Appoints Jeff Points as Chief Financial Officer 72
7.1.7 Jan 29, 2018: Endologix Names Greg Morrow As Chief Marketing Officer 72
7.1.8 Jan 29, 2018: Endologix Appoints Greg Morrow as Chief Marketing Officer 73
7.1.9 Jan 24, 2018: Cardiovascular Systems Appoints Rhonda Robb as New Chief Operating Officer 73
7.1.10 Jan 03, 2018: Tryton Medical Announces New CEO and President 74
7.1.11 Jan 02, 2018: Integer Names Kirk Thor Chief Human Resources Officer 74
7.1.12 Nov 22, 2017: IMRIS Appoints Mark Strong as Senior Vice President - Research & Development 74
7.1.13 Nov 20, 2017: Follicum applies for the start of a Phase II study at the German Medicines Agency 75
7.1.14 Oct 31, 2017: Luminex Corporation Receives FDA Clearance for ARIES Group A Strep Assay 75
7.1.15 Oct 19, 2017: Endologix Appoints John Onopchenko as Chief Operating Officer 77
7.1.16 Oct 04, 2017: Boston Scientific Appoints Desiree Ralls-Morrison General Counsel and Corporate Secretary 77
7.1.17 Oct 02, 2017: Jeffrey H. Burbank Joins CryoLife Board of Directors 78
7.1.18 Sep 26, 2017: Edward Parent Appointed Director of Quality Assurance at TissueGen 78
7.1.19 Aug 28, 2017: Abiomed Announces Resignation of Chief Financial Officer and Welcomes Back Former Chief Financial Officer as Consultant 79
7.1.20 Aug 08, 2017: John K. Bakewell Joins Corindus Vascular Robotics Board of Directors 79
7.1.21 Jul 31, 2017: Atara Biotherapeutics Announces Two Presentations at MSParis2017, Including Updated, Interim Results from a Phase 1 Study of Autologous ATA188 in Patients with Progressive Multiple Sclerosis 80
7.1.22 Jul 18, 2017: AtriCure Announces Hiring of Chief Technology Officer 81
7.1.23 Jul 17, 2017: Integer Announces Appointment of Joseph W. Dziedzic as President and Chief Executive Officer 81
7.1.24 Jun 20, 2017: Medtronic VP and GM Sandra Lesenfants Joins Osprey Board 82
7.1.25 Jun 20, 2017: Medtronic VP and GM Sandra Lesenfants J oins Osprey Board 82
7.1.26 Jun 14, 2017: Spectranetics Announces Election of New Chairperson of the Board of Directors 83
7.1.27 May 26, 2017: Merit Medical Announces Appointment of New Director 83
7.1.28 Apr 19, 2017: TissueGen appoints New Faces for Growing Sales Team 83
7.2 Financial Announcements 84
7.2.1 Mar 14, 2018: Corindus Reports Fourth Quarter and Full Year 2017 Results 84
7.2.2 Mar 07, 2018: CryoLife Reports Fourth Quarter and Full Year 2017 Results 84
7.2.3 Feb 26, 2018: AtriCure Announces Fourth Quarter and Full Year 2017 Financial Results 85
7.2.4 Feb 22, 2018: Integer Holdings Reports Results for Fourth Quarter and Full Year 2017 86
7.2.5 Feb 21, 2018: Endologix Reports Fourth Quarter and Fiscal Year 2017 Financial Results 87
7.2.6 Feb 20, 2018: Philips increases Green Revenues to EUR 10.7 billion, 60% of total sales in 2017 88
7.2.7 Feb 08, 2018: Surmodics Reports First Quarter Fiscal 2018 Results, Updates Fiscal 2018 Guidance 89
7.2.8 Feb 07, 2018: Cardiovascular Systems Reports Fiscal 2018 Second-Quarter Financial Results 89
7.2.9 Feb 01, 2018: Boston Scientific Announces Results for Fourth Quarter and Full Year 2017 90
7.2.10 Feb 01, 2018: Abiomed Announces Q3 FY 2018 Record Revenue of $154 Million, Up 34% Over Prior Year 92
7.2.11 Jan 23, 2018: Glytec's Software Yields Superior Patient Outcomes According to Four New Studies in Journal of Diabetes Science and Technology 92
7.2.12 Jan 09, 2018: Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year Ended December 31, 2017 94
7.2.13 Jan 08, 2018: AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2017 94
7.2.14 Jan 08, 2018: Abiomed Announces Preliminary Q3 FY 2018 Revenue of $154M, Up 34% Over Prior Year 95
7.2.15 Jan 04, 2018: AngioDynamics Reports Fiscal 2018 Second Quarter Financial Results 95
Continue…
Note: If you have any special requirements, please let us know and we will offer you the report as you want.
Browse full report with TOC@ http://orbisresearch.com/reports/index/united-states-interventional-cardiology-market-outlook-to-2025
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Information:
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results